However, to decrease the risk for HCC recurrence post-LT, reducing the calcineurin inhibitors dosage, and combining or completely switching to the mammalian target of rapamycin inhibitors are the preferred immunosuppressor regimens (21). Here, MTOR is linked to hepatocellular carcinoma.